Abstract: A conductive unit, includes a U-phase conductive member, a V-phase conductive member and an insulating cover. The U-phase conductive member include a U-phase bus bar and a molded member molded integrally with the U-phase bus bar. The V-phase conductive member includes a V-phase bus bar and not including the molded member. The insulating cover separates the U-phase bus bar from the V-phase bus bar apart and is supported only by the molded member.

Abstract: A lithium ion secondary battery that includes a positive electrode, a negative electrode, a separator, and a nonaqueous electrolytic solution. Among resistance values of at least three of the following resistance components: diffusion resistance of Li ions in the nonaqueous electrolytic solution; ohmic resistance of the nonaqueous electrolytic solution; ohmic resistance of a positive electrode mixture layer, ohmic resistance of a negative electrode mixture layer; reaction resistance of a surface of a positive electrode active material, reaction resistance of a surface of a negative electrode active material; and diffusion resistance of Li ions in the positive electrode mixture layer, diffusion resistance of Li ions in the negative electrode mixture layer, the resistance values at a position of a mixture layer nearest a current collector are smaller than the resistance values at a position of a mixture layer nearest a separator.

Abstract: The head-position sway measuring device (D) includes a touch panel (1a) that gives the instruction to open or close eyes, an acceleration sensor (2a) that measures a displacement of a head position, and a sway recognition unit (1b) that recognizes a head-position sway value based on the displacement of the head position. The acceleration sensor (2a) measures a first measurement value, which is a measurement value obtained in the eye-open state, and then measures a second measurement value, which is a measurement value obtained in the eye-closed state. The sway recognition unit (1b) recognizes the head-position sway value based on the first measurement value and the second measurement value.

Abstract: A manufacturing method of a secondary battery is provided to improve a manufacturing efficiency of a non-rectangular electrode. The manufacturing method is provided for a secondary battery and includes forming the non-rectangular electrode. The step of forming the electrode includes, prior to forming an electrode precursor by applying an electrode material layer raw material to a metal sheet material that becomes a current collector, controlling a wettability of a local portion of a surface of the metal sheet material to the electrode material layer raw material and forming a wettability control region in the local portion. The local portion becomes a cutaway region of the non-rectangular electrode.

Abstract: A secondary battery including a positive electrode, a negative electrode, and a separator between the positive electrode and the negative electrode. In the secondary battery, at least one of the positive electrode and the negative electrode contains an electrode active material, a carbon nanotube, and a polymer dispersant, and in which the carbon nanotube has a basic site amount relatively larger than an acid site amount, and the polymer dispersant has an acidic functional group.

Abstract: A method for producing a new deafness model animal and a new deafness model animal produced by the method, enabling research that can also be applied to clinical application to a human. The present invention provides a method for producing an acoustic trauma deafness model animal, the method including exposing a non-human primate animal to a sound having a frequency of 1 kHz to 32 kHz and a sound pressure level of 100 dB to 150 dB for 10 minutes to 360 minutes. In addition, the present invention provides an acoustic trauma deafness model animal provided by the method for producing an acoustic trauma deafness model animal.

Abstract: This invention relates to methods for treating hearing loss associated with loss of cochlear hair cells, e.g., caused by noise exposure, using certain gamma secretase inhibitors, in post-neonatal animals, e.g., adolescents and adults.

Abstract: A lithium ion secondary battery that includes a positive electrode, a negative electrode, a separator, a nonaqueous electrolytic solution, and a PTC layer between a positive electrode mixture layer and a positive electrode current collector and/or between a negative electrode mixture layer and a negative electrode current collector, the PTC layer having a positive temperature coefficient of resistance. The PTC layer contains nonconductive filler particles, and the electronic resistance at 120° C. is equal to or more than 100 times the electronic resistance at room temperature.

Abstract: An object of the present invention is to provide novel apoptosis inhibitors and therapeutic agents for inner ear hearing impairment. As a pharmaceutical agent for this purpose, biguanide compounds represented by the following structural formula (I) or a rapamycin derivative represented by the following structural formula (II) as an active ingredient is provided: wherein R1 to R7 are each independently selected from a hydrogen atom, a halogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, a 5- or 6-membered heteroaryl group, or a 5- or 6-membered non-aromatic heterocyclic group, each of which may have a substituent selected from a halogen atom, a cyano group, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkoxy carbonyl group, a C3-8 cycloalkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, and a phenyl group; wherein R1 is a C1-6 alkyl or a C3-6 alkynyl, R2 is H, —CH2-OH or —CH2—CH2OH, and X is ?O, (H, H) or (H, OH).

Abstract: An object of the present invention is to provide novel apoptosis inhibitors and therapeutic agents for inner ear hearing impairment. As a pharmaceutical agent for this purpose, biguanide compounds represented by the following structural formula (I) or a rapamycin derivative represented by the following structural formula (II) as an active ingredient is provided: wherein R1 to R7 are each independently selected from a hydrogen atom, a halogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, a 5- or 6-membered heteroaryl group, or a 5- or 6-membered non-aromatic heterocyclic group, each of which may have a substituent selected from a halogen atom, a cyano group, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkoxy carbonyl group, a C3-8 cycloalkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, and a phenyl group; wherein R1 is a C1-6 alkyl or a C3-6 alkynyl, R2 is H, —CH2-OH or —CH2—CH2—OH, and X is ?O, (H, H) or (H, OH).

Abstract: This invention relates to methods for treating hearing loss associated with loss of cochlear hair cells, e.g., caused by noise exposure, using certain gamma secretase inhibitors, in post-neonatal animals, e.g., adolescents and adults.

Abstract: A manufacturing method of a secondary battery is provided to improve a manufacturing efficiency of a non-rectangular electrode. The manufacturing method is provided for a secondary battery and includes forming the non-rectangular electrode. The step of forming the electrode includes, prior to forming an electrode precursor by applying an electrode material layer raw material to a metal sheet material that becomes a current collector, controlling a wettability of a local portion of a surface of the metal sheet material to the electrode material layer raw material and forming a wettability control region in the local portion. The local portion becomes a cutaway region of the non-rectangular electrode.

Abstract: A lithium ion secondary battery that includes a positive electrode, a negative electrode, a separator, and a nonaqueous electrolytic solution. Among resistance values of at least three of the following resistance components: diffusion resistance of Li ions in the nonaqueous electrolytic solution; ohmic resistance of the nonaqueous electrolytic solution; ohmic resistance of a positive electrode mixture layer, ohmic resistance of a negative electrode mixture layer; reaction resistance of a surface of a positive electrode active material, reaction resistance of a surface of a negative electrode active material; and diffusion resistance of Li ions in the positive electrode mixture layer, diffusion resistance of Li ions in the negative electrode mixture layer, the resistance values at a position of a mixture layer nearest a current collector are smaller than the resistance values at a position of a mixture layer nearest a separator.

Abstract: A lithium ion secondary battery that includes a positive electrode, a negative electrode, a separator, a nonaqueous electrolytic solution, and a PTC layer between a positive electrode mixture layer and a positive electrode current collector and/or between a negative electrode mixture layer and a negative electrode current collector, the PTC layer having a positive temperature coefficient of resistance. The PTC layer contains nonconductive filler particles, and the electronic resistance at 120° C. is equal to or more than 100 times the electronic resistance at room temperature.

Abstract: A method for producing a new deafness model animal and a new deafness model animal produced by the method, enabling research that can also be applied to clinical application to a human. The present invention provides a method for producing an acoustic trauma deafness model animal, the method including exposing a non-human primate animal to a sound having a frequency of 1 kHz to 32 kHz and a sound pressure level of 100 dB to 150 dB for 10 minutes to 360 minutes. In addition, the present invention provides an acoustic trauma deafness model animal provided by the method for producing an acoustic trauma deafness model animal.

Abstract: A lithium ion secondary battery that includes a positive electrode having a positive electrode mixture layer containing a positive electrode active material using a lithium-containing metal phosphate compound having an olivine structure and a conductive aid in a particulate form. Moreover, a negative electrode has a negative electrode mixture layer with a separator interposed between the positive and negative electrodes. The thickness of the positive electrode mixture layer is 75 ?m or less. Furthermore, the positive electrode active material is formed from secondary particles having a diameter of 10 or less, with the secondary particles being formed by flocculating multiple primary particles having a particle size of 1 ?m or less. The conductive aid has one or more constituent particles contained within a range of 5 ?m from a center of the primary particle.

Abstract: This invention relates to methods for treating hearing loss associated with loss of cochlear hair cells, e.g., caused by noise exposure, using certain gamma secretase inhibitors, in post-neonatal animals, e.g., adolescents and adults.

Abstract: An object of the present invention is to provide novel apoptosis inhibitors and therapeutic agents for inner ear hearing impairment. As a pharmaceutical agent for this purpose, biguanide compounds represented by the following structural formula (I) or a rapamycin derivative represented by the following structural formula (II) as an active ingredient is provided: wherein R1 to R7 are each independently selected from a hydrogen atom, a halogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, a 5- or 6-membered heteroaryl group, or a 5- or 6-membered non-aromatic heterocyclic group, each of which may have a substituent selected from a halogen atom, a cyano group, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkoxy carbonyl group, a C3-8 cycloalkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, and a phenyl group; wherein R1 is a C1-6 alkyl or a C3-6 alkynyl, R2 is H, —CH2-OH or —CH2—CH2OH, and X is ?O, (H, H) or (H, OH).

Abstract: An object of the present invention is to provide novel apoptosis inhibitors and therapeutic agents for inner ear hearing impairment. As a pharmaceutical agent for this purpose, biguanide compounds represented by the following structural formula (I) or a rapamycin derivative represented by the following structural formula (II) as an active ingredient is provided: wherein R1 to R7 are each independently selected from a hydrogen atom, a halogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, a 5- or 6-membered heteroaryl group, or a 5- or 6-membered non-aromatic heterocyclic group, each of which may have a substituent selected from a halogen atom, a cyano group, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkoxy carbonyl group, a C3-8 cycloalkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, and a phenyl group; wherein R1 is a C1-6 alkyl or a C3-6 alkynyl, R2 is H, —CH2—OH or —CH2—CH2—OH, and X is ?O, (H, H) or (H, OH).

Abstract: A battery cooling structure includes a cooling plate and an electrically insulative sheet. The cooling plate is to support a cooling surface of a battery module to cool the battery module including a plurality of battery cells arranged side by side. The electrically insulative sheet has an electrical non-conductivity and is disposed between the cooling surface of the battery module and the cooling plate to transfer heat from the cooling surface to the cooling plate.